Our portfolio
Our portfolio of exciting life science and healthcare companies
-
Adora
Adora has developed an AI-driven digital health platform that empowers women and transforms the menopause experience through conversational chat bots, exceptional content and a female-focused brand.
-
ArkVax
LSHTM spin-out leveraging glycoengineering to develop next-gen vaccines for animals and humans.
-
Cardiac Tech
Cardiac Tech is a med-tech company that is changing the safety paradigm in post-cardiac surgical recovery.
-
Coding Bio
Coding.bio is building best-in-class chimeric antigen receptors (CARs) using an AI-first approach combined with its proprietary screening platform to rapidly develop and validate new CARs directed against both existing and novel antigen targets.
-
CoSyne Therapeutics
CoSyne Therapeutics is a computational drug discovery company based in London and Cambridge. They are bringing biology and chemistry to hyper scale compute by combing human tissue with polymathic AI. They are on a mission to push the boundaries of technology to improve the lives of patients. Their first goal is to treat brain cancer.
-
Drishti Discoveries
Drishti Discoveries develops transformative treatments through its proprietary RNA-mediated gene silencing platform.
-
Enhanc3D Genomics
A functional genomics spin-out of the Babraham Institute (Cambridge, UK) whose platform technology links non-coding sequence variants to their target genes in order to identify novel therapeutic targets.
-
Ephyra
A National University of Singapore spin-out pioneering the development of circRNA-based molecular sponges to sequester disease-causing molecules.
-
Erebagen
Erebagen is a spin out of the University of Warwick and has developed a novel chemical synthetic biology platform that unlocks the full industrial potential of microbes to develop treatments for diseases.
-
Indegra Therapeutics
An integrin inhibitor discovery platform, designed to unlock new treatments for multiple diseases.
-
NK:IO
NK:IO is a natural killer cell therapy company that has developed a novel and proprietary method for the differentiation, expansion and activation of NK cells without exhaustion.
-
Octiocor
A spin-out company of the University of Cambridge aiming to prevent heart attacks via high-res coronary artery imaging.
-
Proxximos
{Proxximos have developed a revolutionary digital solution for healthcare infection prevention and control
-
RevoNA
University of Portsmouth spin-out disrupting RNA drug discovery.
-
Semarion
Semarion is a University of Cambridge spin-out that is revolutionising cell-based assays for drug discovery and life sciences through its proprietary SemaCyte® microcarrier platform, which leverages novel materials physics for assay miniaturisation, multiplexing, and automation.
-
Spirea
Spirea is developing the next generation of antibody drug conjugate cancer therapeutics which carry more drug payload to tumour cells, resulting in greater efficacy, tolerability and the ability to treat more cancer patients.
-
Spliceor
Spliceor is an RNA gene therapy company that uses trans-splicing to drive suicide gene expression in specific cell types for selective depletion (e.g. killing cancerous, immune or senescent cells with a pro-drug).
-
StemBond Technologies
University of Cambridge spin-out revolutionising cell culture for regenerative medicine.
-
Tagomics
Tagomics is has developed a comprehensive and disruptive epigenetic biomarker discovery platform to advance non-invasive healthcare.
-
Verinnogen
Verinnogen have developed an innovative device that enhances tumour volume estimation in cancer research.
-
Zygosity
Zygosity's proprietary platform enables significantly enhanced gene editing precision and efficacy by eliminating mosaicism, thereby reducing the time and costs of experiments by orders of magnitude and enabling broader adoption of in vivo and ex vivo CRISPR therapeutic applications.